Biocon Gets USFDA Nod for Generic Anti-Cancer Drug
Feb 06, 2024 19:54
Biocon Ltd receives USFDA approval for Dasatinib tablets, a generic anti-cancer medication, strengthening its portfolio of complex drug products.
Photograph: Kind courtesy Biocon
New Delhi, Feb 6 (PTI) Biocon Ltd on Tuesday said it has received approval from the US health regulator for a generic anti-cancer medication.
The company has received approval from the US Food and Drug Administration (USFDA) for Dasatinib tablets to market in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Biocon said in a regulatory filing.
The approval will further strengthen the company's portfolio of vertically integrated, complex drug products, it added.
Shares of Biocon settled 4.97 per cent higher at Rs 298.75 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.